[PDF] Etiology of dizziness among patients referring to an Iranian ear, nose and throat clinic
M Saeedi, M Ajalloueyan, FZ Abdollahi, M Choobdari - Auditory and Vestibular …, 2018
… in a year, experience vertigo [1], in other words, dizziness affects 20–30%
of the general popu- lation [2]. Dizziness is the main complaint of 6.7% of
patients entering emergency room [3]. In 1952, Dix and Hallpike based on …
of the general popu- lation [2]. Dizziness is the main complaint of 6.7% of
patients entering emergency room [3]. In 1952, Dix and Hallpike based on …
 |  |  |
The Link Between Hearing Loss and Dementia
WCW Do Now
… Tinnitus (Ringing in Ear); Vertigo (Dizziness); Meniere's Disease; Bell's Palsy;
Otosclerosis. Nose & Sinus: Nose & Sinus Overview; Nasal Congestion; Broken Nose;
Rhinitis (Nasal Drainage); Sinusitis (Facial Pressure); Sleep Apnea …
Otosclerosis. Nose & Sinus: Nose & Sinus Overview; Nasal Congestion; Broken Nose;
Rhinitis (Nasal Drainage); Sinusitis (Facial Pressure); Sleep Apnea …
| | |
COMPOSITIONS AND METHODS FOR RECOMBINANT NERVE GROWTH FACTOR
J Wen - US Patent App. 15/892,527, 2018
… NGF variants described herein can be used to treat human neurodegenerative disorders,
such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, Huntington's
chorea, Down's Syndrome, nerve deafness, and Meniere's disease …
such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, Huntington's
chorea, Down's Syndrome, nerve deafness, and Meniere's disease …
| | |
[PDF] POSTOPERATİF BULANTI VE KUSMA
SBÜDY Beyazıt
… KTZ aktivasyonunda, dopamin ve serotonin önemli rol oynar (4, 8).
Tafl›t tutmas› yada Meniere hastal›¤›nda, vestibuler sistemden histaminik
ve muskarinik reseptör- ler arac›l›¤› ile kusma merkezine gelen uyar›lar …
Tafl›t tutmas› yada Meniere hastal›¤›nda, vestibuler sistemden histaminik
ve muskarinik reseptör- ler arac›l›¤› ile kusma merkezine gelen uyar›lar …
| | |
HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
C Jorand-lebrun, R Lan, A Chen, RC Clark - US Patent App. 15/954,759, 2018
The present invention relates to compounds of Formula I and pharmaceutically
acceptable compositions thereof, useful as IRAK inhibitors.
acceptable compositions thereof, useful as IRAK inhibitors.
| | |
Methods and Compositions for Cells Expressing a Chimeric Intracellular Signaling Molecule
CH June, M Milone, Y Zhao, LG Lum, A Thakur - US Patent App. 15/754,227, 2018
The present invention relates to compositions and methods for enhancing
T cell metabolism and activity for more effective adoptive T cell therapy. By
expressing an chimeric antigen receptor and bispec.
T cell metabolism and activity for more effective adoptive T cell therapy. By
expressing an chimeric antigen receptor and bispec.
| | |
Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof
S Gill, M Klichinsky, CH June - US Patent App. 15/747,555, 2018
The present invention includes methods and compositions for treating cancer,
whether a solid tumor or a hematologic malignancy. By expressing a chimeric
antigen receptor in a monocyte, macrophage or d.
whether a solid tumor or a hematologic malignancy. By expressing a chimeric
antigen receptor in a monocyte, macrophage or d.
| | |
Αυτή η ειδοποίηση αποστέλλεται από τον Μελετητή Google. Ο Μελετητής Google είναι μια υπηρεσία που παρέχεται από την Google.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου